Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress

Sesen Bio Reports First Quarter 2021 Financial Results and Commercial Launch Readiness Update in the US for Vicineum™

Voyager Therapeutics Announces First Quarter 2021 Financial Results And Corporate Updates

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

Fulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief Medical Officer

Magenta Therapeutics Reports First Quarter Financial Results And Recent Program Highlights

Faze Medicines Appoints Douglas Kerr, M.D., Ph.D., to its Board of Directors

Sesen Bio Announces Commercial Launch Readiness Progress as the Company Approaches the Potential Approval and Launch of Vicineum™

Jounce Therapeutics Reports First Quarter 2021 Financial Resultsj

MOMA Therapeutics Appoints Peter Hammerman, M.D., Ph.D., as Chief Scientific Officer

Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting

Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

Voyager Therapeutics Announces Upcoming Data Presentations At The American Society Of Gene And Cell Therapy Virtual 2021 Annual Meeting

Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy 24th Annual Meeting

Voyager Therapeutics Receives FDA Clearance Of IND Application For Gene Therapy Candidate VY-HTT01 For Treatment Of Huntington’s Diseasev

Cedilla Therapeutics Appoints Chris Bowden, M.D. to its Board of Directorsc

Ambys Medicines Appoints Alan Smith, Ph.D., Chief Technology Officer

Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors

Goldfinch Bio Expands Board of Directors with Appointments of Meryl Zausner, Hon. William “Mo” Cowan and Tyrell Rivers, Ph.D.

Tango Therapeutics And BCTG Acquisition Corp. Announce Merger Agreement To Create Publicly Listed Precision Medicine Company Focused On The Next Generation Of Targeted Cancer Therapies

Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results And Provides A Corporate Update

Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer

Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting

Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference

Magenta Therapeutics To Participate In The Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference

Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development

Tango Therapeutics Appoints Mace Rothenberg, Md, And Lesley Ann Calhoun, Cpa, To Board Of Directors

Maze Therapeutics Appoints Atul Dandekar as Chief Strategy Officer and Expands Board of Directors

Maze Therapeutics Reveals Its Initial Three Lead Programs Targeting Underlying Genetic Drivers of Life-threatening Diseases

Decibel Therapeutics Added to Russell 2000 Index

Sesen Bio and Qilu Pharmaceutical Announce Approval of IND Application in China for Vicineum™

Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Pliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner

Nurix Therapeutics Announces Collaboration For The Discovery Of Novel Drugs To Treat Pediatric Cancers

Sesen Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for the Company’s Lead Product Candidate Vicineum™

Magenta Therapeutics Presents Final Phase 1 Results Of MGTA-145 Stem Cell Mobilization Clinical Trial And Preclinical Data From Targeted Conditioning Program At The European Society For Blood And Marrow Transplantation (EBMT) 2021 Annual Meeting

insitro Raises $400 Million in Series C Financing

Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Optionj

Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

Fulcrum Therapeutics Announces CEO Transition

Magenta Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Program Highlights

Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress

GBT Opens 2021 ACCEL Grant Program, Providing up to $500,000 in Support to the Sickle Cell Disease Community

Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results

bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111)

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

Sesen Bio Announces FDA Acceptance and Priority Review of its Biologics License Application for Vicineum™

Nurix Therapeutics Reports Fourth Quarter And Fiscal Year 2020 Financial Results And Provides A Corporate Update